Connect with us
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

News

SoCalBio Announces Presenting Companies for 3rd Digital Health Conference

gbafNews28

The Southern California Biomedical Council (SoCalBio) “ the voice and advocate for the bioscience and digital health industries in the Greater Los Angeles region — today announced its final list of 12 companies selected to present at the 3rd Digital Health Conference (SoCalBioDH.com).

The conference, which will be held on Friday, December 13th at the historic Hotel Casa del Mar on the beach in Santa Monica, serves as a showcase for the latest advances in data mining and analytics to help diagnose and treat medical conditions.

In addition to keynote presentations and panel discussions, the conference will feature presentations by the following companies working to transform health data and analytics:

  • BioStrap (Wearables that employ machine learning to deliver highly-accurate activity and wellness tracking)
  • Coala Life (Smart cardiac monitors to detect Atrial Fibrillation)
  • Deep 6 AI (AI-enabled systems to match patients with clinical trials)
  • Doctor Evidence (Curated, user-friendly relational databases to serve organizations across the evidence-based medicine spectrum)
  • Eyenuk (A platform to eliminate avoidable blindness using artificial intelligence)
  • FocusMotion (Remote orthopedic patient monitoring platform that uses machine learning to automatically track pre and post op therapy compliance, minimize complications, and reduce recovery time)
  • Hexoskin (Smart, clinically validated garments to monitor cardiac, respiratory, sleep, and activity data)
  • NoVaResp Technologies (Respiratory monitoring device and algorithm that helps positive airway pressure (PAP) machines respond proactively with tailored preemptive therapy for sleep apnea)
  • Perimetrics LLC (AI-driven dental diagnostics)
  • TrialStat (A new paradigm In eClinical and data management solutions)
  • Theseus AI (Machine learning to aid back pain treatment)
  • TigoHealth (Health data aggregation and analysis for personal health insights, healthcare systems support, and development of life-saving drugs)

The above companies were screened and selected by members of SoCalBios Innovation Catalyst Program, a unique network of senior bioscience and healthcare professionals who also provide presentation and business coaching for SoCalBio conferences presenters.

This years list of presenting companies is representative of the many innovative digital health ventures across the Greater Los Angeles region that are working to reimagine healthcare, said Peter Blaisdell, Ph.D., board member of Afecta Pharmaceuticals and chair of SoCalBios Innovation Catalyst Program. They offer a preview of the future of value-based healthcare, and we hope the conference provides them with opportunities to increase their visibility and access resources needed for success.

SoCalBio President and CEO Ahmed Enany added, We welcome the 2019 presenters to be part of the growing SoCalBio family of companies working to drive change in healthcare delivery. They are helping cement the Los Angeles regions status as a leading center for health and wellness.

In addition to emerging company presentations, this years SoCalBio Digital Health Conference will feature keynote sessions focused on the opportunities and challenges of integrating new technologies such as artificial intelligence and machine learning into the spectrum of care.

Distinguished speakers include:

  • Steve Rimar, President & CEO of Analytica Consulting, will open the conference with a presentation titled From Visualization to Machine Learning – How Different Healthcare Verticals Utilize Data Analytics.
  • Milo Bissin, Director of Life Science & Healthcare at Silicon Valley Bank, will deliver a presentation titled Who Is Investing in Digital Health and Analytics Development, Where, and Why?
  • Emmanuel Fombu, MD, Author and Digital Health Futurist, will deliver the luncheon keynote on How the Internet of Things (IoT), Artificial Intelligence (AI), and Machine Learning Are Revolutionizing the Healthcare Industry.
  • Thomas Priselac, President & CEO, Cedars Sinai Medical Center, will participate in a discussion on how healthcare providers can accelerate digital innovation adoption.
  • Wade Ackerman, Partner at Covington, will deliver a presentation titled The Digital Health Industrys Regulatory Challenges.

The conference will also tap prominent L.A. region investors and business development professionals to examine the factors that drive funding and corporate partnerships in the digital health industry. Participants include:

  • Luke Hayes, Managing Director, Torrent Ventures
  • Yiwen Li, Director of Strategy & Business Development, NantHealth
  • John Shen, Founding Partner, Sunstone Management
  • Kwame Ulmer, Venture Partner, Wavemaker Three-Sixty Health
  • Richard Weil, Partner, Mount Wilson Ventures
  • Kevin Zhang, Partner, Upfront Ventures

SoCalBio thanks the following sponsors for their support:

About the SoCalBio Digital Health Conference

The SoCalBio Digital Health Conference is a showcase for digital innovations poised to disrupt the $3.7 trillion US healthcare system. It is also a forum for providers, payers, entrepreneurs and investors to share information on how digitization can help improve care while reducing costs. More information is available at https://www.socalbiodh.com.

About SoCalBio

SoCalBio is a nonprofit, member-supported trade association that promotes bioscience research, development, manufacturing, job creation and overall economic growth in the Greater Los Angeles region. The Councils programs help local firms gain access to capital, potential partners and business support services. SoCalBio also promotes technology transfer and workforce training, while informing policy makers and the public-at-large about the benefits of the LA regions life-science industry. More information about SoCalBio is available at www.socalbio.org.

Erik Deutsch

ExcelPR Group

323-851-2300 x112

erikd[at]excelpr[dot]com

News

Structural changes required to make Japan’s health system sustainable, according to Economist Intelligence Unit report

gbafNews28

  • Challenges from ageing populations and covid-19 are putting pressure on Japan’s health system
  • Japan’s health system falls behind its peers in terms of long-term strategic perspective
  • Price review and setting mechanism introduces unintended inefficiencies in the health system and act as a brake on structural reform

TOKYO, JAPAN – Media OutReach – 23 September 2020 – Japan’s healthcare system has kept the country remarkably healthy with relatively minor changes for nearly six decades. The system provides universal care, extensive coverage and the most innovative treatments at a cost that is accessible to all. Yet the scope of coverage in the Japanese system obscures the extent to which policymakers have put off making necessary but difficult choices. In particular, the lack of regulation of demand for health services, the pressures of an ageing population and the underdeveloped system for determining cost-benefit for health investments could paralyse Japan’s healthcare system as the cost of providing health services increase. The economic consequences of this would inevitably reverberate beyond the health system itself.

 

Sustainable health systems not only have appropriate resources to effectively function but are also capable of keeping up with developments and overcoming hurdles. Health systems must be able to address challenges and demonstrate the political will required to explore and implement innovative designs for health services. For Japan, evolving population demographics and financial pressures represent two of the biggest hurdles for sustainability.

 

Health system sustainability in Japan is a report by The Economist Intelligence Unit, sponsored by Pfizer. It examines the challenges and opportunities that Japan’s healthcare system is facing and the sustainability of its current system compared with those of other developed industrial countries. The research uses a scorecard to compare Japan’s performance against those of five other countries across a number of domains, including disease prevention, integrated health models, the medical workforce and long-term care.

 

The research points to signs that significant fixes to Japan’s healthcare system may be necessary for Japan’s health system to maintain long-term stability. Although Japan compares well in many respects to the more expensive and fragmented system in the US, it lags behind the UK, France or South Korea, in three of the five principal scoring domains Japan received its highest scores in the domains covering disease prevention and health infrastructure, and accountability and patient-centredness, and lowest in long-term strategic perspective and provision of integrated care models. Key issues that Japan’s health system must overcome to maintain long-term stability include changing incentives for healthcare utilization where currently prices are kept low but there is no limit on demand; an overhaul of time-consuming biannual price reviews; and better use of cost-saving generic and biosimilar drugs.

 

Jesse Quigley Jones, editor of the report, said, “Japan’s health system is justly praised for its high-quality and generous coverage, however it’s long-term sustainability is increasingly under question. The covid-19 pandemic has highlighted vulnerabilities of the system with experts warning of the collapse of the emergency medicine system, and potential knock-on effects for the broader health system and even overall economy. Our research has highlighted some positive steps towards reform and an emerging long-term vision, but further political commitment is needed to make evidence-based decisions and ensure Japan’s health system is sustainable for generations to come.”

About the research

Health system sustainability in Japan is a report by The Economist Intelligence Unit, sponsored by Pfizer. It examines the challenges and opportunities that Japan’s healthcare system is facing and the sustainability of its current system compared with those of other developed industrial countries. The research uses a scorecard to compare Japan’s performance against those of five other countries  across a number of domains, including financing, cost-benefit analysis, workforce issues, medical research and long-term care.


About The Economist Intelligence Unit

The Economist Intelligence Unit is the world leader in global business intelligence. It is the business-to-business arm of The Economist Group, which publishes The Economist newspaper. The Economist Intelligence Unit helps executives make better decisions by providing timely, reliable and impartial analysis on worldwide market trends and business strategies.

More information can be found at www.eiu.com or [View Image]www.twitter.com/theeiu

About Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.comglobaland www.pfizer.co.jp (Japan)

Continue Reading

News

The Law Offices of Frank R. Cruz Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

gbafNews28

The Law Offices of Frank R. Cruz announces an investigation of NextCure, Inc. (NextCure or the Company) (NASDAQ: NXTC) on behalf of investors concerning the Companys possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On January 13, 2020, NextCure disclosed that Eli Lilly and Company had ended its collaboration agreement for the research and development of the Companys leading product candidate, NC318, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor particularly for patients with advanced or metastatic solid tumors.

On this news, the Companys share price fell $4.70, or 8%, to close at $52.00 per share on January 13, 2020, thereby injuring investors.

Then, on July 13, 2020, before the market opened, NextCure announced that it was no longer planning to advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial. The same day, the Company announced that its Chief Medical Officer resigned.

On this news, the Companys share price fell $9.73, or 54%, to close at $8.15 per share on July 13, 2020, thereby injuring investors further.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased NextCure securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

[email protected]

www.frankcruzlaw.com

Continue Reading

News

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of GoHealth, Inc. (GOCO) on Behalf of Investors

gbafNews28

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GoHealth, Inc. (GoHealth or the Company) (NASDAQ: GOCO) investors concerning the Companys possible violations of the federal securities laws.

If you suffered a loss on your GoHealth investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/gohealth-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

In July 2020, GoHealth sold approximately 43.5 million shares of stock in its initial public stock offering (the “IPO”), at $21.00 per share raising almost $914 million in new capital.

Then, on August 19, 2020, in its first quarterly earnings report following the IPO, GoHealth announced that it incurred a net loss of $22.9 million after posting net income of $15.3 million in the prior-year period.

On this news, the Company’s stock price fell $1.99 per share, or 10%, to close at $17.03 per share on August 20, 2020, thereby injuring investors.

On September 15, 2020, GoHealths stock price closed at $12.53, a 40% decline from its IPO price.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding GoHealth should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPMs nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPMs lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPMs attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPMs past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barrons, Investors Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

Continue Reading
gbafNews28 gbafNews28
News50 mins ago

Structural changes required to make Japan’s health system sustainable, according to Economist Intelligence Unit report

Challenges from ageing populations and covid-19 are putting pressure on Japan’s health system Japan’s health system falls behind its peers...

gbafNews28 gbafNews28
News2 hours ago

Instrumentation Services Market: COVID-19 Business Continuity Plan | Evolving Opportunities With ABB Ltd. and Agilent Technologies Inc. | Technavio

The global instrumentation services market size is expected to grow by USD 1.31 billion as per Technavio. This marks a...

gbafNews28 gbafNews28
News2 hours ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of GoHealth, Inc. (GOCO) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an...

gbafNews28 gbafNews28
News2 hours ago

The Law Offices of Frank R. Cruz Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of NextCure, Inc. (NextCure or the Company) (NASDAQ: NXTC) on...

gbafNews28 gbafNews28
News2 hours ago

Laird Superfood Announces Pricing of Initial Public Offering

Laird Superfood, Inc. (Laird Superfood) today announced the pricing of its initial public offering of 2,650,000 shares of its common...

gbafNews28 gbafNews28
News2 hours ago

Fluor Corporation to Hold 2019 10K Earnings Conference Call

Fluor Corporation (NYSE: FLR) will hold a conference call to review results for its 2019 10-K for the period ended...

gbafNews28 gbafNews28
News2 hours ago

Galvanized Steel Market – Post Pandemic Business Strategies and Processes Plan | Economic Growth in China and India to Boost Growth in the Materials Industry | Technavio

The galvanized steel market is expected to grow by 35.18 million MT during 2020-2024, expanding at a CAGR of almost...

gbafNews28 gbafNews28
News2 hours ago

Vecima Declares Quarterly Dividend

Vecima Networks Inc. (TSX: VCM) today announced that, consistent with its previously announced dividend policy, the Board of Directors has...

gbafNews28 gbafNews28
News2 hours ago

Phytech Raises $23.5 Million in Growth Funding From THL Automation Fund and Existing Anchor Investors

Phytech Ltd. (Phytech or the Company), a digital farming automation and data provider, and Thomas H. Lee Partners, L.P. (“THL”),...

gbafNews28 gbafNews28
News2 hours ago

Kemper Prices $400 Million Senior Notes Offering

Kemper Corporation (NYSE: KMPR) announced today that it has priced a registered offering of $400 million of 2.400% senior notes...